{"organizations": [], "uuid": "676d7eda55ca084b6d07a1fea4e7767859266a46", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/usa-healthcare-gottlieb/fda-head-gottlieb-criticizes-industry-for-kabuki-drug-pricing-idUSL2N1QP0YD", "country": "US", "domain_rank": 408, "title": "FDA head Gottlieb criticizes industry for Kabuki drug-pricing", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-07T23:24:00.000+02:00", "replies_count": 0, "uuid": "676d7eda55ca084b6d07a1fea4e7767859266a46"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/usa-healthcare-gottlieb/fda-head-gottlieb-criticizes-industry-for-kabuki-drug-pricing-idUSL2N1QP0YD", "ord_in_thread": 0, "title": "FDA head Gottlieb criticizes industry for Kabuki drug-pricing", "locations": [], "entities": {"persons": [{"name": "gottlieb", "sentiment": "negative"}, {"name": "scott gottlieb", "sentiment": "negative"}, {"name": "yasmeen abutaleb", "sentiment": "none"}, {"name": "chizu nomiyama", "sentiment": "none"}], "locations": [{"name": "washington", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WASHINGTON, March 7 (Reuters) - U.S. Food and Drug Administrator Scott Gottlieb on Wednesday criticized drugmakers, pharmacy benefit managers and health insurers for “Kabuki drug-pricing constructs” that he said expose consumers to high out-of-pocket costs and discourage competition.\nGottlieb delivered the remarks at an annual conference of health insurers in a speech largely aimed at promoting biosimilars, rival treatments that are as effective as the original but cheaper. But he criticized much of the health industry for failing to promote access to innovative treatments such as biosimilars and for pricing practices that harm consumers.\nKabuki is a form of Japanese theater known for its dramatization and elaborate make-up of its performers. (Reporting by Yasmeen Abutaleb Editing by Chizu Nomiyama)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T23:24:00.000+02:00", "crawled": "2018-03-08T17:11:06.001+02:00", "highlightTitle": ""}